CLEVELAND—Lubrizol Corp.'s LifeSciences business is investing $15 million to expand its global manufacturing facilities, which will position LifeSciences to better serve the medical device contract manufacturing market.
This capital investment will expand multiple facilities, Lubrizol said, while increasing Lubrizol LifeSciences' in-house engineering capacity for both silicone and thermoplastic products.
“We have significantly enhanced our capabilities through the combination of strong polymer technology, application know-how and world-class component manufacturing,” said Deb Langer, vice president and general manager, Lubrizol LifeSciences.
“As health care companies look for total solution providers, we continue to invest in the right areas to provide valuable offerings to our customers.”
Vesta Inc. was acquired by Lubrizol in Aug. 2014 and is a contract manufacturer for the global medical device industry. Its acquisition expanded Lubrizol LifeSciences product portfolio and it now offers disposable and implantable silicone medical components and assemblies across a wide product portfolio, as well as precision thermoplastic extruded tubing.
Additionally, Lubrizol LifeSciences recently acquired Particle Sciences Inc., a contract drug development and manufacturing organization, which has positioned Lubrizol LifeSciences as one of the most comprehensive drug delivery device solution providers, the company said, offering end-to-end solutions in the health care market.
“When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process,” said Robert Miller, global business director, medical devices.
“With a long history of polymer expertise and significant investment, Lubrizol LifeSciences is positioned to offer full-service development for next generation medical and pharmaceutical innovations.”